XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 3 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner. The Company manages its business primarily by managing its international network of independent consultants through similar commission plans. Most products available to customers in the United States are available to customers across all markets internationally. These products are purchased through third-party manufacturers by the Company's corporate office in the United States and sold to each international market. Pricing for all products is determined at the Company's corporate office in the United States. Accordingly, for disclosure purposes, the Company has a single reporting segment, which is reported on the Company’s consolidated financial statements.
The Chief Operating Decision Maker (“CODM”) is the Company’s Chief Executive Officer. The CODM regularly reviews consolidated financial information and performance used to make decisions about the Company as a whole and without distinguishing or grouping of operations based on asset type, revenue, geographic location, tenant or other factors.
The CODM evaluates performance through consolidated financial budget-to-actual variances on a monthly and quarterly basis and allocates resources based on net income as reported in the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. Total expenditures for long-lived assets are reported on the consolidated statements of cash flows.

The following table presents the Company’s segment revenue and expenses and segment net income for the three months ended September 30, 2025 and 2024 (in thousands):

 Three Months Ended September 30,
 20252024
Revenue, net$47,561 $47,214 
Cost of sales(9,745)(9,491)
Consultant commissions(19,385)(19,093)
Consultant incentives, promotions, and recognition(1,310)(1,212)
Labor and benefits(6,836)(7,117)
Stock compensation(826)(917)
Events(531)(189)
Depreciation and amortization(610)(797)
Credit card and bank processing fees(1,337)(1,409)
Other segment items(1)
(4,827)(4,470)
Interest income97 67 
Interest expense(10)(8)
Income tax expense(86)(752)
Net income$2,155 $1,826 
(1) Other general and administrative expenses include legal, professional services, rent, utilities, and other miscellaneous expenses.
The following table presents the Company’s long-lived assets for its most significant geographic markets (in thousands):
 September 30, 2025June 30, 2025
United States$14,143 $18,446 
Foreign:
Japan1,716 1,901 
Other foreign markets427 472 
Total foreign markets2,143 2,373 
Total long-lived assets$16,286 $20,819 
The Company has identified two major markets with revenues exceeding 10% of consolidated total revenue: the United States and Japan. There are 16 other markets, each of which individually is less than 10% of consolidated total revenue. Sales are recorded in the market in which the transaction occurred. The following table presents the Company’s revenue disaggregated by these markets (in thousands):
 Three Months Ended September 30,
 20252024
United States$35,216 $35,268 
Foreign:
Japan6,192 5,983 
Other foreign markets6,153 5,963 
Total foreign markets12,345 11,946 
Total revenue, net$47,561 $47,214 
Major Products
The Company’s revenue for the three months ended September 30, 2025 and 2024 is largely attributed to three product lines: Protandim®, TrueScience®, and LifeVantage®. On a combined basis, these three product lines represent approximately 86.2% and 86.6% of the Company’s total net revenue for the three months ended September 30, 2025 and 2024, respectively. The following table shows revenue by product line for the three months ended September 30, 2025 and 2024 (in thousands):
Three Months Ended September 30,
20252024
Protandim® product line
$22,057 $24,198 
TrueScience® product line
9,867 12,792 
LifeVantage® product line
9,105 3,902 
AXIO® product line
3,458 3,532 
PhysIQ™ product line
1,236 1,144 
Petandim® product line
477 534 
Other(1)
1,361 1,112 
Total revenue, net$47,561 $47,214 
(1) Other revenue includes shipping and handling revenue, event related revenue, and other revenues impracticable to allocate to a specific product line.